Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma
Key Points
Key Points
- Nasopharyngeal carcinoma (NPC) is uncommon in many jurisdictions but remains a significant public health problem in East and Southeast Asia, which accounted for more than 70% of the approximate 129,000 new diagnoses worldwide in 2018.
- NPC relies almost exclusively on (chemo-)radiotherapy to achieve disease control in most presentations, particularly in the definitive treatment of stage II to IVA disease.
Treatment
...Treatment...
...Radiotherapy: For Pat...
...1.1For all nasopharyngeal carcinoma...
...mendation 1.2For all NPC patients, both seq...
...ndation 1.3For all NPC patients, a prescribed dose...
...mendation 1.4For all NPC patients,...
...ation 1.5For NPC patients who have unde...
...dation 1.6The delineation of elective no...
...Chemo...
...ion 2.1For T2N0 (AJCC 8th) NPC patients, chemother...
...ecommendation 2.2For T1-2N1 (AJCC 8th) NPC patien...
...2.3For Stage III–IVA (except T3N0) (AJCC 8...
....4For Stage III–IVA (except T3N0) (AJCC 8th)...
...mmendation 2.5For T3N0 (AJCC 8th) NPC...
...Concur...
...mendation 3.1For all NPC patients w...
...ommendation 3.2For all NPC patients without cont...
...on 3.3For NPC patients with a contra...
...on 3.4For NPC patients with a contraindicatio...
...Ind...
...dation 4.1For all NPC patients receiv...
...4.2For NPC patients receiving induction c...
...ommendation 4.3For NPC patients receiv...
...Adjuv...
...mendation 5.1For all NPC patients receiving...
...ation 5.2For all NPC patients receiving ad...
...ecommendation 5.3For all NPC patients receiv...
...age II to IVA Nasopharyngeal Carcinoma...